TG Therapeutics (TGTX) Reports Q4 Loss of $0.37/Share

TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.37), versus ($0.48) reported last year. Revenue for the quarter came in at $38.1 million, versus $38.1 million reported last year.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• CrowdStrike shares jump on earnings beat, raised outlook
• CrowdStrike Holdings Inc. (CRWD) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY Guidance
• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance